NEURO-NET® BRAIN-DERIVED EXOSOME CAPTURE NEURO-NET is a specific exosome capture tool designed for isolation of brain-derived exosomes for use in neurological applications. NEURO-NET has been analytically and clinically validated for isolation of brainderived EVs in Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). NEURO-NET is available to academic and industry researchers for research collaborations. On 20 August 2024, INOVIQ announced that it had further validated its NEURO-NET™ technology for isolation of brain-derived exosomes in Parkinson’s Disease (PD). Initial analytical and clinical validation studies in PD showed that NEURO-NET enriched known protein biomarkers of neurodegenerative diseases by 5-8-fold and over 200 proteins were identified that were either decreased (blue) or increased (red) in PD patients when compared to normal healthy individuals (Figure 1, data obtained from 10 cases of PD and 10 healthy controls). INOVIQ also progressed discussions and evaluations with several academic groups, diagnostic and biopharma companies to assess NEURO-NET’s potential in diagnostic applications for brain cancer, neurodegenerative and neuropsychiatric disorders. Successful outcomes from these evaluations are anticipated to result in research collaborations and/or supply agreements for NEURO-NET. The next milestones for NEURO-NET include collecting further clinical validation data and fostering partnerships with both academic institutions and industry leaders in the field of neurological conditions. hTERT ICC TEST The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used in a clinical setting as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer The hTERT test is registered as an IVD medical device in the United States (Class I IVD) for use as a clinical diagnostic by pathology laboratories for the detection of hTERT in cytopathology samples.8 The hTERT test is sold direct to laboratory customers in the US achieving revenues of $294,314 during the year (2024: $333,255). hTERT revenues are expected to remain flat in FY2026 due to the limited market size and increased competition from new products. Proteins present in NEURO-NET captured exosomes from Parkinson’s Disease and normal healthy individuals. INTELLECTUAL PROPERTY PORTFOLIO The Group owns or exclusively licenses a broad intellectual property (IP) portfolio of granted patents, patent applications, trade secrets and trademarks protecting INOVIQ’s technologies, products, processes and brands. The Group had 22 granted patents, 15 patents pending and 1 provisional patent application as at 30 June 2025, covering its Molecular NET, Exosome therapeutics, SubB2M, BARD1 and hTERT technologies and products across key jurisdictions including the United States, Europe, Asia, and Australia. Trademarks are also registered or pending for INOVIQ®, EXO-NET®, Sienna Cancer Diagnostics® and Acuris®. INOVIQ filed or advanced several patent applications to expand its exosome intellectual property (IP) portfolio during the period: › On 18 October 2024, INOVIQ filed international PCT application AU2024/051103 entitled ‘Extracellular vesicle compositions and uses thereof’ protecting its NEURO-NET technology for isolation of brain-derived exosomes. › On 29 May 2025, INOVIQ’s collaborator the University of Queensland filed Australian Provisional Patent Application 2025902121 entitled ‘Diagnostic signature’ to secure intellectual property rights covering various protein and RNA biomarker combinations and methods for the exosome ovarian cancer test. 8 Allison et al. Evaluation of Sienna Cancer Diagnostics hTERT Antibody on 500 Consecutive Urinary Tract Specimens. Acta Cytologica 2018. DOI: 10.1159/000489181 Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information 9 Annual Report 2025
RkJQdWJsaXNoZXIy MjE2NDg3